Clinical Trials Browser

Phase 2 × Interventional × rucaparib × Clear all

NCT03694262 2026-04-13

EndoBARR

Phase 2 Completed

30 enrolled 7 charts

Endometrial Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2 Active not recruiting

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT03617679 2026-03-24

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2 Completed

79 enrolled 12 charts

Endometrial Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT04276376 2025-12-01

ARIANES

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT04624178 2025-11-20

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Phase 2 Active not recruiting

Leiomyosarcoma

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

ATM Gene Mutation

NCT02678182 2025-06-10

PLATFORM

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT03639935 2025-06-03

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Phase 2 Completed

32 enrolled 14 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03845296 2025-05-21

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Completed

64 enrolled 17 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03958045 2024-10-22

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Phase 2 Completed

33 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03413995 2024-10-16

TRIUMPH

Phase 2 Completed

12 enrolled 11 charts

Prostate Cancer Metastatic

NCT01074970 2024-09-19

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Phase 2 Completed

135 enrolled 14 charts

Breast Neoplasms

NCT03533946 2024-03-13

ROAR

Phase 2 Terminated

7 enrolled 10 charts

Prostatic Neoplasms

NCT03476798 2024-02-15

Clovis-001

Phase 2 Completed

49 enrolled 13 charts

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03140670 2023-09-28

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Phase 2 Terminated

46 enrolled 16 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02042378 2023-06-13

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01891344 2023-06-12

ARIEL2

Phase 2 Completed

491 enrolled 19 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT02952534 2023-06-09

TRITON2

Phase 2 Completed

277 enrolled 23 charts 3 FDA

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02505048 2021-06-08

RUBY

Phase 2 Completed

Breast Neoplasms

NCT03795272 2019-11-01

MaRuC

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT00664781 2016-05-24

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Phase 2 Completed

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms